| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Penicillin-binding proteins (PBPs). Cefcapene, the active metabolite of cefcapene pivoxil, functions as a beta-lactam antibiotic by binding to specific PBPs located on the inner membrane of the bacterial cell wall. This inhibits the transpeptidase and carboxypeptidase enzymes involved in the cross-linking of the peptidoglycan layer, thereby disrupting bacterial cell wall synthesis. This mechanism leads to osmotic instability and ultimately bacterial lysis and death, with enhanced Gram-negative coverage typical of third-generation cephalosporins.
|
|---|---|
| ln Vitro |
Cefcapene exhibits a broad in vitro antibacterial spectrum, being active against clinically relevant pathogens including Staphylococcus spp., Streptococcus spp., Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Minimum inhibitory concentration (MIC₉0) values typically range from 0.1 to 4 microg/mL for susceptible organisms. It shows particular effectiveness in treating palmoplantar pustulosis (PPP), a chronic inflammatory skin condition, potentially due to its antibacterial and immunomodulatory effects on tonsillar foci.
|
| ln Vivo |
Cefcarpine hydrochloride (oral; 100 mg/kg; 4 days) is efficacious against invasive BLNAR strains in the lungs of mice. It is predicted that the highest concentration of antibiotics in the blood of mice is 1 to 2 μg/30 to 120 minutes after intragastric treatment. ml[3].
In a mouse lung infection model, cefcapene pivoxil hydrochloride (100 mg/kg oral administration for 4 days) is effective against invasive BLNAR strains. In mice, intragastric administration achieves peak antibiotic concentrations of 1 to 2 microg/ml in the blood from 30 to 120 minutes post-dose. In clinical studies, it is well-tolerated and effective for treating bacterial infections, showing significant improvement in clinical symptoms of conditions like PPP. |
| Enzyme Assay |
The standard in vitro susceptibility test follows CLSI guidelines. A bacterial suspension (0.5 McFarland standard) is swabbed onto Mueller-Hinton agar plates. Etest strips containing a gradient of cefcapene are placed on the agar. Alternatively, broth microdilution is performed in 96-well plates with serial 2-fold dilutions of cefcapene (0.015-64 microg/mL). Minimum Inhibitory Concentrations (MICs) are read after 18-24 hours of incubation at 35degC as the lowest concentration preventing visible growth.
|
| Cell Assay |
To assess cytotoxicity, human cell lines (e.g., HEK-293 or HepG2) are seeded in 96-well plates and treated with serial dilutions of cefcapene pivoxil HCl (0.1-1000 microM) for 48 hours. Cell viability is measured using a CCK-8 or MTT reagent, with absorbance measured at 450 nm. The compound should show low cytotoxicity (CC₅0 > 100 microg/mL) compared to its antibacterial MICs to ensure a therapeutic window.
|
| Animal Protocol |
Animal/Disease Models: 4weeks old female C57BL/6J mice, BSG bacterial suspension (1×109 CFU) [3]
Doses: 100 mg/kg Route of Administration: Oral; 100 mg/kg; 4 days Experimental Results: Inhibition of influenza virus Haemobacilli colonize mouse lungs. The in vivo protocol uses four-week-old female C57BL/6J mice with a bacterial suspension in BSG (1×10⁹ CFU). Cefcapene pivoxil hydrochloride is administered orally at a dose of 100 mg/kg for 4 days to assess its efficacy against H. influenzae colonization in the mouse lung. |
| ADME/Pharmacokinetics |
After oral administration of cefcapene pivoxil HCl, the prodrug is well absorbed and rapidly hydrolyzed to the active cefcapene. Its oral bioavailability is estimated to be high in humans. The active drug is primarily excreted renally as unchanged cefcapene. The plasma elimination half-life (t1/2) in healthy subjects is approximately 1-2 hours, supporting typical dosing intervals of 2-3 times daily. The compound has a molecular weight of 604.10.
|
| Toxicity/Toxicokinetics |
Cefcapene pivoxil HCl is generally well-tolerated in clinical studies. The most common adverse effects are gastrointestinal (diarrhea, nausea, abdominal pain) and are usually mild to moderate. As with other cephalosporins, there is a potential for hypersensitivity reactions (rash, urticaria), with cross-sensitivity to penicillins occurring in about 5-10% of patients. Pivalate esters like this prodrug can lead to carnitine depletion with long-term use.
|
| References |
|
| Additional Infomation |
Cefcapene pivoxil HCl is a third-generation cephalosporin that has been clinically used (primarily in Japan and China) for treating bacterial infections and is approved for systemic use in those regions. It is not approved by the FDA for use in the United States. Its unique application includes research into palmoplantar pustulosis (PPP) with pustulotic arthro-osteitis. The compound has a molecular formula of C23H30ClN5O8S2.
|
| Molecular Formula |
C23H30CLN5O8S2
|
|---|---|
| Molecular Weight |
604.0960
|
| Exact Mass |
603.122
|
| CAS # |
147816-23-7
|
| Related CAS # |
Cefcapene pivoxil hydrochloride hydrate;147816-24-8;Cefcapene pivoxil;105889-45-0
|
| PubChem CID |
6918126
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.382
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
39
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
Cl[H].S1C([H])([H])C(C([H])([H])OC(N([H])[H])=O)=C(C(=O)OC([H])([H])OC(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=O)N2C([C@]([H])([C@@]12[H])N([H])C(/C(/C1=C([H])SC(N([H])[H])=N1)=C(/[H])\C([H])([H])C([H])([H])[H])=O)=O
|
| InChi Key |
ALPFRUJYOAKQQR-CQZSJNSUSA-N
|
| InChi Code |
InChI=1S/C23H29N5O8S2.ClH/c1-5-6-12(13-9-38-21(24)26-13)16(29)27-14-17(30)28-15(11(7-34-22(25)33)8-37-18(14)28)19(31)35-10-36-20(32)23(2,3)4;/h6,9,14,18H,5,7-8,10H2,1-4H3,(H2,24,26)(H2,25,33)(H,27,29);1H/b12-6-;/t14-,18-;/m1./s1
|
| Chemical Name |
2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~206.92 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.33 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.33 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.33 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6554 mL | 8.2768 mL | 16.5536 mL | |
| 5 mM | 0.3311 mL | 1.6554 mL | 3.3107 mL | |
| 10 mM | 0.1655 mL | 0.8277 mL | 1.6554 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
